Traffic Lights - Latest Updates

Last updated: 20/08/2019

Other updates on this site
Drug Name Classification Clinical Indication Comments
5-AMINOLAEVULINIC ACID GEL (Ameluz®) Black Actinic keratosis
AVIPTADIL/PHENTOLAMINE intracavernosal injection (Invicorp®) (UPDATED) Green Erectile dysfunction
BENRALIZUMAB (NEW) Red Severe Eosinophilic Asthma

In line with NICE TA565 Implementation date 6th June 2019

BICTEGRAVIR, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE (Biktarvy®) (NEW) Black HIV

Not yet reviewed

BREXPIPRAZOLE (Rexulti ®) (NEW) Black Antipsychotics

LPT prescribing group have reviewed and found no significant advantages over existing formulary products

BROMOCRIPTINE (UPDATED) Amber Simple Hyperprolactinaemic disorders

Annual monitoring undertaken in secondary care Primary care should be aware of fibrotic reactions

BUDESONIDE (1mg orodipersible tablet) (Jorveza®) (NEW) Black Eosinophilic esophagitis

Not yet reviewed.

BUROSUMAB (Crysvita®) (NEW) Black X-linked hypophosphataemia in children and young people

Not yet reviewed

CABERGOLINE (UPDATED) Amber Simple Hyperprolactinaemic disorders

Annual monitoring undertaken in secondary care Primary care should be aware of fibrotic reactions

CANAGLIFLOZIN / METFORMIN (Vokanamet®) Black Type 2 diabetes

Not yet reviewed

CARIPRAZINE(Reagila®) (UPDATED) Red Schizophrenia

As per LPT managed entry requirements

CEFTAZIDIME / AVIBACTAM (Zavicefta®) (UPDATED) Red As per antimicrobial advice

Prescribe by brand to prevent confusion.

CEFTOLOZANE-TAZOBACTAM (Zerbaxa®) (NEW) Red As per antimicrobial advice
CIPROFLOXACIN HYDROCHLORIDE 3mg / FLUOCINOLONE ACETONIDE 0.25mg (Cetraxal Plus®) (NEW) Black Acute otitis externa (AOE). Acute otitis media in patients with tympanostomy (AOMT)

Not yet reviewed.

CITALOPRAM (UPDATED) Amber Simple Mental health indications as per the children’s BNF for children and young people
COBICISTAT / ELVITEGRAVIR / EMTRICITABINE / TENOFOVIR (Stribild) Red HIV
DALBAVANCIN (UPDATED) Red Bacterial skin infections

As per antimicrobial working party recommendations

DALTEPARIN (UPDATED) Green Thromboprophylaxis and Treatment of DVT
DARVADSTROCEL (Alofisel®) (UPDATED) Black Complex perianal fistulas in adults with Crohn’s disease

Not recommended by NICE TA 556

DEKAS (UPDATED) Amber Simple Vitamin Supplement for paediatric and adult patients with cystic fibrosis
DEKAS VITAMINS (various formulations) (NEW) Black Depending on formulation, bariatric surgery or liver disease

Not yet reviewed

DESMOPRESSIN ORAL LYOPHILISATE (Noqdirna ®) (NEW) Green Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults

To be started in primary care only. Please click drug name for more information.

DOLUTEGRAVIR WITH LAMIVUDINE (Dovato®) (NEW) Black HIV

Not yet reviewed

DONEPEZIL (UPDATED) Amber Simple Alzheimer's disease

In line with NICE NG 97

Change in traffic light status from 1st October 2018.

DOXYLAMINE SUCCINATE AND PYRIDOXINE (Xonvea®) (NEW) Black Nausea and vomiting in pregnancy

Not yet reviewed

ENOXAPARIN (UPDATED) Red Thromboprophylaxis and treatment of DVT

Courses started during the dalteparin shortage can be continued to be supplied in primary care

ERENUMAB 70mg injection (NEW) Black Migraine prophylaxis

Not yet reviewed.

ERTUGLIFLOZIN (Steglatro®) (UPDATED) Green Conditional Type 2 diabetes mellitus (for 18 years and over) as monotherapy

In line with NICE TA 572
Conditional on prescriber being competent to select appropriate patients
Implementation date 27th June 2019

ERTUGLIFLOZIN (Steglatro®) (UPDATED) Amber Simple Type 2 diabetes mellitus (for 18 years and over) as monotherapy or with metformin

In line with NICE TA 572
Monotherapy is simple amber if the prescriber does not feel competent to initiate.

Implementation date 27th June 2019

FLUOXETINE (UPDATED) Amber Simple Mental health indications as per the children’s BNF for children and young people
FreeStyle Libre® Sensor (UPDATED) Amber Simple Diabetes glucose monitoring inline with NHSE criteria.

As per LMSG freestyle libre documents An initiation letter is required for an initial  six month trial. Continuation dependent on letter detailing improvement in the NHSE England parameters. 

 

FREMANEZUMAB (Ajovy ®) (NEW) Black Migraine prophylaxis

Not reviewed

GALCANEZUMAB (Emgality ®) (NEW) Black Migraine prophylaxis

Not yet reviewed

GUSELKUMAB (UPDATED) Red Moderate to severe plaque psoriasis in adults

In line with NICE TA 521.

 

INSULIN ASPART (Fiasp®) (UPDATED) Green Conditional Type 1 and 2 diabetes mellitus in adults

Conditional on prescriber being competent to select appropriate patients.

LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (Levosert®) (UPDATED) Green Contraception or heavy menstrual bleeding
LUBIPROSTONE (UPDATED) Green Chronic refractory constipation
MELATONIN (Colonis®) (NEW) Black Jet lag
MELATONIN M/R 1mg and 5mg tablets (Slenyto ®) (UPDATED) Black Treatment of insomnia not covered by the simple amber status
MELATONIN M/R 1mg and 5mg tablets (Slenyto®) (UPDATED) Amber Simple Insomnia for children aged 2-18 years with Autism Spectrum Disorder and or Smith-Magenis.

New patients only

MEMANTINE (UPDATED) Amber Simple Alzheimer's disease

in line with NICE NG 97

Change in traffic light status from 1st October 2018

NALOXONE nasal spray (Nyxoid®) (NEW) Black Opioid overdose

Not yet reviewed.

NONACOG BETA PEGOL (Refixia®) (NEW) Black Haemophilia B

Not yet reviewed.

OCRELIZUMAB (NEW) Red Relapsing-remitting multiple sclerosis

In line with NICE TA 533

Implementation date 25th October 2018

ONDANSETRON (UPDATED) Green Nausea

Further information when used for palliative care can be found in the Palliative Care Prescribing Guide

OSPEMIFENE (Senshio®) (NEW) Black Vulvar and vaginal atrophy in post-menopausal women

Not yet reviewed

PRASTERONE 6.5mg PESSARY (Intrarosa®) (NEW) Black Vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms

Not yet reviewed.

PRUCALOPRIDE (UPDATED) Green Chronic refractory constipation
RAVULIZUMAB (Ultomiris®) (NEW) Black Paroxysmal nocturnal haemoglobinuria

Not yet reviewed

RISANKIZUMAB (Skyrizi®) (NEW) Black Psoriasis

Not yet reviewed

RIVASTIGMINE (UPDATED) Amber Simple Alzheimer's disease

in line with NICE NG 97

Change in traffic light status from 1st October 2018

SEMAGLUTIDE (Ozempic®) (UPDATED) Green Conditional GLP 1 analogue

Conditional on prescriber being competent to select appropriate patients.

SERTRALINE (UPDATED) Amber Simple Mental health indications as per the children’s BNF for children and young people
SODIUM HYALURONATE, CO-ENZYME Q10 AND VITAMIN E COMBINATION EYE DROP (VisuXl ®) (NEW) Green Severe dry eye and corneal healing post-surgery
SODIUM ZIRCONIUM (Lokelma®) (NEW) Black Hyperkalemia

Not yet reviewed

SYMTUZA® (NEW) Red Combination HIV treatment

As part of NHS England Clinical Commissioning policy

TERIPARATIDE (UPDATED) Red Osteoporosis in men and women
TOFACITINIB (NEW) Red Moderately to severely active ulcerative colitis

In line with NICE TA 547

Implementation date 28th February 2019

TRICHLOROACETIC ACID (NEW) Red Resolution of cyst in enucleated socket
TRICLABENDAZOLE (NEW) Red Hepatic fascioliasis

Approved by the Antimicrobial Working Party

ULIPRISTAL ACETATE (Esmya ®) (UPDATED) Red Uterine fibroids

In line with MHRA alert August 2018 regarding risks of liver injury.

Other Updates on this Website

Recent documents from LMSG and TAS

Shortage of Megace® (194 KB)

We have been notified that there are supply problems with Megace® (megestrol acetate) tablets which is expected to last for 5-6 weeks.

Date added: 4th Jul 2019

About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more